Vesikari T, André F E, Simoen E, Florent G, Ala-Laurila E L, Heikkinen A, Kuusinen H, Terho A
Acta Paediatr Scand. 1983 Jan;72(1):37-40. doi: 10.1111/j.1651-2227.1983.tb09660.x.
Urabe Am 9, a new strain of mumps vaccine, originally developed in Japan, was evaluated in children 14 to 20 months of age in a comparative trial with the Jeryl Lynn strain. Both vaccines performed well. The antibody responses were measured using a neutralization test and a haemolysis-in-gel test. The seroconversion rates at six weeks, as detected with either one or both tests, were 55/58 (94.8%) after the Urabe Am 9 and 58/60 (96.7%) after the Jeryl Lynn vaccine. Only mild infrequent adverse reactions were observed. It is concluded that both strains of live attenuated mumps vaccine are immunogenic and well-tolerated in this age group.
Urabe Am 9是一种新的腮腺炎疫苗株，最初在日本研发，在一项针对14至20个月大儿童的比较试验中与Jeryl Lynn株进行了评估。两种疫苗表现都良好。使用中和试验和凝胶溶血试验测量抗体反应。在六周时，无论用一种或两种试验检测，Urabe Am 9疫苗后的血清转化率为55/58（94.8%），Jeryl Lynn疫苗后为58/60（96.7%）。仅观察到轻微且不常见的不良反应。得出的结论是，两种减毒活腮腺炎疫苗株在该年龄组中都具有免疫原性且耐受性良好。
